Literature DB >> 11570877

Insulin regulation of gene expression through the forkhead transcription factor Foxo1 (Fkhr) requires kinases distinct from Akt.

J Nakae1, T Kitamura, W Ogawa, M Kasuga, D Accili.   

Abstract

Insulin inhibits expression of certain liver genes through the phosphoinositol (PI) 3-kinase/Akt pathway. However, whether Akt activity is both necessary and sufficient to mediate these effects remains controversial. The forkhead proteins (Foxo1, Foxo3, and Foxo4, previously known as Fkhr or Afx) are transcriptional enhancers, the activity of which is inhibited by insulin through phosphorylation-dependent translocation and nuclear exclusion. Others and we have previously shown that the forkhead protein Foxo1 is phosphorylated at three different sites: S(253), T(24), and S(316). We have also shown that T(24) fails to be phosphorylated in hepatocytes lacking insulin receptors, and we have suggested that this residue is targeted by a kinase distinct from Akt. In this study, we have further analyzed the ability of Akt to phosphorylate different Foxo1 sites in control and insulin receptor-deficient hepatocytes. Expression of a dominant negative Akt (Akt-AA) in control hepatocytes led to complete inhibition of endogenous Akt, but failed to inhibit Foxo1 T(24) phosphorylation and, consequently, insulin suppression of IGFBP-1 promoter activity. Conversely, expression of a constitutively active Akt (Akt-Myr) in insulin receptor-deficient hepatocytes led to an overall increase in the level of Foxo1 phosphorylation, but failed to induce T(24) and S(316) phosphorylation. These data indicate that the Foxo1 T(24) and S(316) kinases are distinct from Akt, and suggest that the pathways required for insulin regulation of hepatic gene expression diverge downstream of PI 3-kinase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11570877     DOI: 10.1021/bi015532m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  A kinase in the life of the beta cell.

Authors:  D Accili
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization.

Authors:  Li Qiang; Alexander S Banks; Domenico Accili
Journal:  J Biol Chem       Date:  2010-06-02       Impact factor: 5.157

3.  CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPAR delta/beta-mediated adaptation to metabolic stress.

Authors:  Zaher Nahlé; Michael Hsieh; Terri Pietka; Chris T Coburn; Paul A Grimaldi; Michael Q Zhang; Debopriya Das; Nada A Abumrad
Journal:  J Biol Chem       Date:  2008-02-28       Impact factor: 5.157

4.  Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.

Authors:  Arvind Dasari; Alexandria Phan; Sanjay Gupta; Asif Rashid; Sai-Ching Jim Yeung; Kenneth Hess; Helen Chen; Emily Tarco; Huiqin Chen; Caimiao Wei; Kim Anh-Do; Daniel Halperin; Funda Meric-Bernstam; James Yao
Journal:  Endocr Relat Cancer       Date:  2015-04-21       Impact factor: 5.678

5.  How to explain the AKT phosphorylation of downstream targets in the wake of recent findings.

Authors:  Anil K Agarwal
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-15       Impact factor: 11.205

6.  Dissociation of the glucose and lipid regulatory functions of FoxO1 by targeted knockin of acetylation-defective alleles in mice.

Authors:  Alexander S Banks; Ja Young Kim-Muller; Teresa L Mastracci; Natalie M Kofler; Li Qiang; Rebecca A Haeusler; Michael J Jurczak; Dina Laznik; Garrett Heinrich; Varman T Samuel; Gerald I Shulman; Virginia E Papaioannou; Domenico Accili
Journal:  Cell Metab       Date:  2011-11-02       Impact factor: 27.287

7.  Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms.

Authors:  Xiangshan Zhao; Lixia Gan; Haiyun Pan; Donghui Kan; Michael Majeski; Stephen A Adam; Terry G Unterman
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

8.  Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice.

Authors:  Tracie A Seimon; Yibin Wang; Seongah Han; Takafumi Senokuchi; Dorien M Schrijvers; George Kuriakose; Alan R Tall; Ira A Tabas
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

9.  Arrestin domain-containing 3 (Arrdc3) modulates insulin action and glucose metabolism in liver.

Authors:  Thiago M Batista; Sezin Dagdeviren; Shannon H Carroll; Weikang Cai; Veronika Y Melnik; Hye Lim Noh; Suchaorn Saengnipanthkul; Jason K Kim; C Ronald Kahn; Richard T Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-10       Impact factor: 11.205

10.  STAT3 targets the regulatory regions of gluconeogenic genes in vivo.

Authors:  Preeti Ramadoss; Nathan E Unger-Smith; Francis S Lam; Anthony N Hollenberg
Journal:  Mol Endocrinol       Date:  2009-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.